Archive


Category: AT-527

  • Atea Reports Results of AT-527 in P-II MOONSONG Trial for the Treatment of COVID-19

    Shots: The P-II MOONSONG trial evaluates the antiviral activity, safety & PK of AT-527 (550/1100 mg, bid) vs PBO in adult patients with COVID-19. The therapy is jointly developed in collaboration with Roche The trial did not meet its 1EPs of reduction from baseline in SARS-CoV-2 virus in an overall study population, two-thirds of patients […]

  • Atea Presents Results of AT-527 in P-I Study for COVID 19 at CROI

    Shots: The P-I study involves assessing the safety and PK of AT-527 (550 mg, q2, BID) vs PBO for 5 days in 20 healthy volunteers in a ratio (1:1) to treat COVID-19 The result showed rapid attainment of steady state levels within 2days of dosing, predicted lung AT-9010 levels were consistently above the EC90 level […]

  • Roche Concludes the License Agreement with Chugai for AT-527 to Treat COVID-19 in Japan

    Shots: Chugai gets exclusive development and commercializing rights for AT-527 in Japan Earlier, Roche and Atea collaborated to jointly develop AT-527. If approved, Atea to distribute AT-527 in the US and Roche will be responsible for global manufacturing and distribution outside the US AT-527 is an investigational, oral, purine nucleotide prodrug, currently being evaluated in […]

  • Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19

    Shots: The companies will collaborate to develop, manufacture, and distribute AT-527 to combat COVID-19. If approved, Atea will be responsible for distributing the treatment option in the US, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the US The therapy is currently being evaluated in P-II study for […]